Review Highlights CRISPR-Modified Mesenchymal Stromal Cells for Bone and Cartilage Repair

Targeted genetic manipulation of mesenchymal stromal cells using CRISPR-Cas9 genome editing represents a promising strategy to enhance therapeutic potential and develop the next generation of regenerative treatments for skeletal diseases, according to a review published in the Journal of Translational Medicine. In the field of regenerative medicine, mesenchymal stromal cells rank among the best-characterized cell types because they can be readily expanded in culture, possess the capacity to differentiate into various tissues and cells, and display inherent immunomodulatory characteristics. However, mesenchymal stromal cells have limited therapeutic efficacy. This restricted efficacy stems from several persistent physiological obstacles: transplanted cells suffer from low survival rates, exhibit significant cellular heterogeneity, and routinely lose their ability to function after transplantation. The emergence of new advances in CRISPR-Cas9 genome editing has opened the door to targeted genetic manipulation of these cells, ushering in an era of improved regenerative potential that is particularly relevant for cartilage and bone repair.

The published review focuses directly on recent advances in employing CRISPR-modified mesenchymal stromal cells for musculoskeletal regeneration. Within this domain, research efforts place particular emphasis on five core biological processes necessary for skeletal restoration: promoting osteogenesis, chondrogenesis, angiogenesis, immunomodulation, and extracellular matrix remodeling.

Preliminary studies evaluated in the review have identified several key molecular targets that provide promising therapeutic potential when modulated via CRISPR-Cas9. Among these, the transcription factor RUNX2 has been established as a primary target associated with positive differentiation outcomes in regenerative settings. Another identified target is CXCR4, which is linked to tissue-specific homing. Furthermore, researchers identified IL-10 as an anti-inflammatory target. Additionally, PD-L1 has been identified as an immunomodulatory target with promising therapeutic potential.

Furthermore, cell-free therapeutic approaches have gained increasing attention. These approaches are based on the secretome and extracellular vesicles engineered with mesenchymal stromal cells. In conjunction with cell-free modalities, recent research has concentrated on enhancing musculoskeletal tissue regeneration by integrating genetically engineered mesenchymal stromal cells into biomaterials and hydrogel systems. Studies have also focused on using genetically engineered mesenchymal stromal cells in scaffold-based systems.

Although preclinical results across these diverse experimental platforms are encouraging, several critical challenges continue to hinder the translation of CRISPR-engineered mesenchymal stromal cells into clinical practice. The review identifies major technical and safety obstacles that must be resolved, including off-target effects generated during genome editing, the long-term genomic stability of edited cells, delivery efficiency into target tissues, manufacturing standardization across production batches, and broader long-term safety concerns. Most importantly, the authors note that no clinical trials have registered the use of mesenchymal stromal cells engineered with CRISPR for cartilage or bone regeneration. This complete absence of registered human clinical trials underscores an ongoing disconnect between experimental laboratory progress and clinical use in patients suffering from skeletal diseases.

Subject of Research: CRISPR-engineered mesenchymal stromal cells for cartilage and bone repair

Article Title: CRISPR-engineered mesenchymal stromal cells for cartilage and bone repair

Article References: Ashayeri, M., Rahimian, S., Sheikh, H., & Babashah, S. (2026). CRISPR-engineered mesenchymal stromal cells for cartilage and bone repair. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09187-7

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09187-7

Keywords: mesenchymal stromal cells, CRISPR-Cas9, cartilage repair, bone repair, musculoskeletal regeneration, osteogenesis, chondrogenesis, extracellular vesicles, CRISPR-engineered, mesenchymal, stromal, cells